FDA OKs accelerated approval pathway for AngioDynamics' NanoKnife for pancreatic cancer; shares up 1% after hours

|By:, SA News Editor

AngioDynamics (NASDAQ:ANGO) is up 1% after hours in response to its announcement that the FDA has granted Expedited Access Pathway (EAP) status for its NanoKnife System for the treatment of Stage III (cancer has spread, but not metastasized) pancreatic cancer.

The goal of the EAP program is to enable timely patient access to medical devices that may provide more effective treatment than standard-of-care or for which no approved alternatives exist. It provides for accelerated agency review and the involvement of more senior FDA personnel.

The NanoKnife uses low-energy direct current electrical pulses to permanently open pores in target cell membranes which kills the cells. It is currently approved in the U.S. for the surgical ablation of soft tissue.

Subscribe for full text news in your inbox